Reported Earnings • Apr 26
Full year 2025 earnings released: EPS: NT$1.65 (vs NT$1.51 in FY 2024) Full year 2025 results: EPS: NT$1.65 (up from NT$1.51 in FY 2024). Revenue: NT$219.7m (up 7.0% from FY 2024). Net income: NT$23.5m (up 9.2% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Apr 15
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 9.1% to NT$17.90. The fair value is estimated to be NT$14.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%. 공시 • Apr 01
RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026 RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$218.6m market cap, or US$6.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Jan 14
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$212.8m market cap, or US$6.72m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Buy Or Sell Opportunity • Dec 16
Now 21% overvalued Over the last 90 days, the stock has fallen 7.6% to NT$17.00. The fair value is estimated to be NT$14.10, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%. Buy Or Sell Opportunity • Nov 26
Now 21% overvalued Over the last 90 days, the stock has fallen 5.7% to NT$17.30. The fair value is estimated to be NT$14.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%. Buy Or Sell Opportunity • Nov 11
Now 21% overvalued Over the last 90 days, the stock has fallen 2.0% to NT$17.55. The fair value is estimated to be NT$14.53, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%. Upcoming Dividend • Sep 25
Upcoming dividend of NT$0.30 per share Eligible shareholders must have bought the stock before 02 October 2025. Payment date: 31 October 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.7%). 공시 • Mar 31
RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025 RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city Taiwan New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$260.2m market cap, or US$7.90m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Dec 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$254.3m market cap, or US$7.75m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.1% average weekly change). New Risk • Nov 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$267.3m market cap, or US$8.32m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.4% average weekly change). Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 44% over the past three years. Valuation Update With 7 Day Price Move • Oct 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to NT$22.70, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total returns to shareholders of 59% over the past year. Upcoming Dividend • Sep 12
Upcoming dividend of NT$0.56 per share Eligible shareholders must have bought the stock before 19 September 2024. Payment date: 18 October 2024. Payout ratio is on the higher end at 75%, however this is supported by cash flows. Trailing yield: 5.6%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (1.2%). Upcoming Dividend • Jul 29
Upcoming dividend of NT$0.44 per share Eligible shareholders must have bought the stock before 05 August 2024. Payment date: 30 August 2024. Payout ratio is on the higher end at 89%, and the cash payout ratio is above 100%. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (1.3%). Reported Earnings • Apr 25
Full year 2023 earnings released: EPS: NT$0.50 (vs NT$0.29 in FY 2022) Full year 2023 results: EPS: NT$0.50 (up from NT$0.29 in FY 2022). Revenue: NT$172.5m (flat on FY 2022). Net income: NT$6.43m (up 70% from FY 2022). Profit margin: 3.7% (up from 2.2% in FY 2022). 공시 • Apr 12
RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024 RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024. New Risk • Feb 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.3x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (NT$209.6m market cap, or US$6.63m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Buy Or Sell Opportunity • Feb 20
Now 23% undervalued Over the last 90 days, the stock has risen 5.3% to NT$15.90. The fair value is estimated to be NT$20.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Jan 22
Now 20% undervalued Over the last 90 days, the stock has risen 4.8% to NT$15.25. The fair value is estimated to be NT$19.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making. Buying Opportunity • Jan 16
Now 21% undervalued Over the last 90 days, the stock is up 3.8%. The fair value is estimated to be NT$19.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making. Buying Opportunity • Nov 29
Now 20% undervalued Over the last 90 days, the stock is up 3.7%. The fair value is estimated to be NT$19.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making. Upcoming Dividend • Jul 06
Upcoming dividend of NT$1.12 per share at 6.2% yield Eligible shareholders must have bought the stock before 13 July 2023. Payment date: 11 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 6.2%. Within top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.0%). Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to NT$21.25, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 40% over the past year. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to NT$17.75, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 49% over the past year. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improved over the past week After last week's 20% share price gain to NT$17.70, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total loss to shareholders of 43% over the past year. Valuation Update With 7 Day Price Move • Apr 18
Investor sentiment improved over the past week After last week's 19% share price gain to NT$47.15, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 35x in the Life Sciences industry in Asia.